Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 
+44 28 3718 0055Journal of Genetic Disorders & Genetic ReportsISSN: 2327-5790
Eleonora Riccio Author
Subjects of specialization
Affiliation
Enzyme replacement therapy
Department of Neuroscience, Division of Obstetrics and Gynecology, Reproductive and Odontostomatological Sciences, Federico II University of Naples, Italy
Biography
Mr. Eleonora Riccio, belongs to the department of Public Health, interest in the field of Fabry disease; Enzyme replacement therapy; Agalsidase alfa, from niversity of Naples, Naples, 80131, Italy
Publications
Case Report Subscription
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease
Author(s):
Antonio Pisani, Giuseppe Bifulco, Attilio Di Spiezio Sardo and Eleonora Riccio
Introduction: Enzyme replacement therapy (ERT) is the cornerstone of the treatment of Fabry disease (FD), with either agalsidase alfa or beta. Both preparations have been shown to be safe and effective in patients with FD, but there are very few data on the safety of ERT during pregnancy. Here we report a case of a 22-year-old woman with FD who received ERT with agalsidase alfa during the pregnancy.
Case report: The patient, a 22-year-old woman, was diagnosed with FD three years prior to pregnancy. Because of the presence of pain and proteinuria, she started treatment with agalsidase alfa (0.2 mg/kg every 2 weeks) with a substantial amelioration of the view more»
Google Scholars / Researchers Sites
